SANA - Sana Biotechnology, Inc.
IEX Last Trade
1.59
0.005 0.314%
Share volume: 28,187
Last Updated: Fri 27 Dec 2024 08:30:31 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$1.58
0.01
0.32%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
4.29%
1 Month
-33.33%
3 Months
-60.28%
6 Months
-68.52%
1 Year
-60.19%
2 Year
-46.71%
Key data
Stock price
$1.59
DAY RANGE
$1.56 - $1.66
52 WEEK RANGE
$1.70 - $12.00
52 WEEK CHANGE
-$58.33
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Steven D. Harr
Region: US
Website: sana.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: sana.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Sana Biotechnology, Inc. focuses on utilizing engineered cells as medicines. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia. SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus. SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease.
Recent news